TransMedics (TMDX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

TransMedics reported Q3 2026 revenue of $203.01 million, up 41.2% year-over-year, beating the consensus estimate of $181.81 million by 11.66%. EPS came in at $0.51, delivering an 88.89% surprise versus the $0.27 consensus estimate. Key metrics showed strong performance across most segments, particularly in international markets and service revenue. However, the stock has declined 10.3% over the past month and carries a Zacks Rank #3 (Hold) rating.